biological source
goat
conjugate
peroxidase conjugate
antibody form
affinity isolated antibody
antibody product type
secondary antibodies
clone
polyclonal
form
lyophilized powder
species reactivity
monkey
technique(s)
immunohistochemistry: suitable, indirect ELISA: suitable, western blot: suitable
shipped in
wet ice
storage temp.
2-8°C
General description
抗体类型：IgG
Immunogen
猴IgAα重链
Biochem/physiol Actions
本产品采用单特异性抗血清，通过免疫亲和色谱法制备，使用猴IgA偶联琼脂糖珠，然后进行固相吸附，以去除任何不希望的反应。通过免疫电泳分析，产生了针对抗过氧化物酶、抗山羊血清、猴IgA和猴血清的单一沉淀弧。未观察到针对猴IgM或猴IgG的反应。
Physical form
在0.02 M磷酸钾、0.15 M氯化钠（pH 7.2）和10 mg/mL牛血清白蛋白（BSA）中提供-无免疫球蛋白和蛋白酶
Preparation Note
用1.0 mL去离子水（或等效物）复溶。
Disclaimer
对于美国客户：含汞；请勿放入生活垃圾桶 - 请根据当地、州或联邦法律进行处理。
除非我们的产品目录或产品附带的其他公司文档另有说明，否则我们的产品仅供研究使用，不得用于任何其他目的，包括但不限于未经授权的商业用途、体外诊断用途、离体或体内治疗用途或任何类型的消费或应用于人类或动物。
Still not finding the right product?
试用我们的 产品选型工具 工具缩小选择范围
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 2 Dermal - Acute Tox. 3 Oral - Acute Tox. 4 Inhalation - Aquatic Chronic 2 - STOT RE 2
target_organs
Kidney
存储类别
6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
常规特殊物品
含少量动物源组分生物产品
此项目有
Eirikur Saeland et al.
NPJ vaccines, 8(1), 45-45 (2023-03-24)
Respiratory syncytial virus (RSV) is a leading cause of severe respiratory disease for which no licensed vaccine is available. We have previously shown that a prefusion (preF) conformation-stabilized RSV F protein antigen and an adenoviral vector encoding RSV preF protein
Ruklanthi de Alwis et al.
Emerging microbes & infections, 10(1), 1457-1470 (2021-06-15)
Zika virus (ZIKV) is an emerging arbovirus with recent global expansion. Historically, ZIKV infections with Asian lineages have been associated with mild disease such as rash and fever. However, recent Asian sub-lineages have caused outbreaks in the South Pacific and
Ahmed O Hassan et al.
Cell reports. Medicine, 2(4), 100230-100230 (2021-03-24)
The deployment of a vaccine that limits transmission and disease likely will be required to end the coronavirus disease 2019 (COVID-19) pandemic. We recently described the protective activity of an intranasally administered chimpanzee adenovirus-vectored vaccine encoding a pre-fusion stabilized spike